Membranoproliferative glomerulonephritis secondary prevention

Membranoproliferative glomerulonephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Membranoproliferative glomerulonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Membranoproliferative glomerulonephritis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Membranoproliferative glomerulonephritis secondary prevention
CDC on Membranoproliferative glomerulonephritis secondary prevention
Membranoproliferative glomerulonephritis secondary prevention in the news
Blogs on Membranoproliferative glomerulonephritis secondary prevention
Directions to Hospitals Treating Membranoproliferative glomerulonephritis
Risk calculators and risk factors for Membranoproliferative glomerulonephritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:

Overview

Secondary prevention of strategy is a method to reduce the complication of disease, and one of the most important complication of MPGN is end-stage renal disease (ESRD).

Secondary prevention

Effective measures for the secondary prevention of MPGN include medications to reduce the progression of ESRD which include:

• Angiotensin-converting enzyme (ACE) inhibitors
• Angiotensin-receptor blockers
• Combined ACE inhibition and angiotensin receptor antagonism
• Dietary protein restriction